Grifols Therapeutics Llc
Clinical trials sponsored by Grifols Therapeutics Llc, explained in plain language.
-
Two-Year safety check for promising Alpha-1 lung therapy
Disease control ENROLLING_BY_INVITATIONThis study aims to gather two more years of safety data for a weekly intravenous treatment in people with lung damage caused by Alpha-1 Antitrypsin Deficiency. It is an extension of a previous trial, enrolling about 290 participants who will receive the treatment for 104 weeks. T…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Three-Year trial tests weekly infusions to slow lung damage in genetic emphysema
Disease control OngoingThis study is testing whether weekly intravenous infusions of a replacement protein can slow the progression of lung damage in people with emphysema caused by Alpha-1 antitrypsin deficiency. About 345 participants will receive either one of two doses of the protein therapy or a p…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC